Kuvan (Sapropterin Dihydrochloride)

Sapropterin dihydrochloride supplies tetrahydrobiopterin, the natural cofactor required by phenylalanine hydroxylase. By increasing cofactor availability, the drug enhances the enzymatic conversion of phenylalanine to tyrosine, thereby decreasing phenylalanine concentrations in the bloodstream of responsive patients.

The dosage of Kuvan is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, baseline phenylalanine levels, and response to therapy. Patients should follow the prescribing clinician’s instructions and undergo regular monitoring.

Kuvan is classified as pregnancy category B, indicating that animal studies have not shown risk, but there are limited human data. It may be used during pregnancy only if the potential benefit outweighs any possible risk. Breastfeeding mothers should exercise caution and discuss potential infant exposure with their healthcare provider.

To request Kuvan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kuvan is a synthetic form of tetrahydrobiopterin, whereas many other PKU therapies rely solely on dietary restriction of phenylalanine. For patients who are tetrahydrobiopterin‑responsive, Kuvan can increase phenylalanine tolerance and reduce dietary burden, offering a pharmacologic alternative to strict protein limitation.

Kuvan tablets should be stored at ambient temperature below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in humid or excessively hot environments, and keep the product out of reach of children.

Kuvan is taken orally as a tablet. The tablet should be swallowed whole with water, unless the prescriber provides specific instructions for crushing or splitting the dose. Administration is usually performed once daily, but the exact schedule is determined by the treating physician.

Serious risks, although rare, include hypersensitivity reactions such as anaphylaxis, severe skin reactions like Stevens‑Johnson syndrome, significant liver enzyme elevations, and thrombocytopenia. Patients should be instructed to seek immediate medical attention if they experience signs of an allergic reaction, rash, jaundice, or unusual bleeding.

Kuvan is contraindicated in patients with known hypersensitivity to sapropterin dihydrochloride or any of its excipients. It should also be avoided in individuals who are not responsive to tetrahydrobiopterin, as the medication will not provide therapeutic benefit in those cases.